Literature DB >> 380689

Successful allogeneic bone marrow retransplantation with the same donor after graft rejection: application of a modified conditioning regimen.

J Gmür, P G Frick, A von Felten.   

Abstract

A 26-year-old man with severe aplastic anemia was treated with high-dose Cyclophosphamide followed by the infusion of bone marrow cells from his HLA-identical sister. After initial intake of the graft, rejection ensued by day 46 which was followed by a permanent complete aplasia. After 4 months, bone marrow retransplantation with the same donor was attempted after a more intensive conditioning regimen. This led to permanent engraftment with rapid normalization of the blood counts lasting now for over 12 months. The patient has since remained in excellent clinical condition without signs of graft-versus-host disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 380689     DOI: 10.1007/bf01008074

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  12 in total

1.  Selection of patients for bone marrow transplantation in severe aplastic anemia.

Authors:  B M Camitta; J M Rappeport; R Parkman; D G Nathan
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  One-hundred-ten patients with aplastic anemia (AA) treated by marrow transplantation in Seattle.

Authors:  R Storb; E D Thomas; P L Weiden; C D Buckner; R A Clift; A Fefer; B W Goodell; F L Johnson; P E Neiman; J E Sanders; J Singer
Journal:  Transplant Proc       Date:  1978-03       Impact factor: 1.066

3.  Allogeneic bone marrow transplantation in aplastic anemia--report of 25 cases.

Authors:  E Gluckman; A Devergie; M Marty; A Bussel; J Rottemboúrg; J Dausset; J Bernard
Journal:  Transplant Proc       Date:  1978-03       Impact factor: 1.066

4.  Aplastic anaemia treated by marrow transplantation.

Authors:  E D Thomas; R Storb; A Fefer; S J Slichter; J I Bryant; C D Buckner; P E Neiman; R A Clift; D D Funk; K E Lerner
Journal:  Lancet       Date:  1972-02-05       Impact factor: 79.321

5.  Technique for human marrow grafting.

Authors:  E D Thomas; R Storb
Journal:  Blood       Date:  1970-10       Impact factor: 22.113

6.  Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test.

Authors:  K K Mittal; M R Mickey; D P Singal; P I Terasaki
Journal:  Transplantation       Date:  1968-11       Impact factor: 4.939

7.  Histocompatibility matching. VI. Miniaturization of the mixed leukocyte culture test: a preliminary report.

Authors:  R J Hartzman; M Segall; M L Bach; F H Bach
Journal:  Transplantation       Date:  1971-03       Impact factor: 4.939

8.  Identification of high-risk patients with aplastic anaemia in selection for allogeneic 0one-marrow transplantation.

Authors:  H P Lohrmann; P Kern; D Niethammer; H Heimpel
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321

9.  Pretransplant lymphocytotoxins and bone-marrow graft rejection.

Authors:  R P Gale; J H Fitchen; M Cahan; G Opelz; M J Cline
Journal:  Lancet       Date:  1978-01-28       Impact factor: 79.321

10.  Bone-marrow transplantation in severe aplastic anaemia.

Authors: 
Journal:  Lancet       Date:  1976-10-30       Impact factor: 79.321

View more
  1 in total

1.  Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.

Authors:  J Bolaños-Meade; L Luznik; M Muth; W H Matsui; C A Huff; B D Smith; M Y Levy; Y L Kasamon; L J Swinnen; J D Powell; R A Brodsky; R F Ambinder; R J Jones; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-11-03       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.